T2 Biosystems (TTOO) said Monday it extended its multiyear capital equipment supplier agreement with Vizient until March 31, 2026.
The contract covers products such as the T2Dx instrument, the T2Bacteria panel and the T2Candida panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood, the company said.
T2 Biosystems shares were up 3.6% in recent trading.
Price: 0.38, Change: +0.01, Percent Change: +3.56
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments